NEOGENOMICS 2026 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance: NeoGenomics reported Q2 revenue of $201.7 million, up 11% year over year and ahead of guidance. Clinical revenue grew 14% driven by 2% volume growth and 12% AUP growth, with NGS revenue up 26% and now about one-third of clinical revenue. Adjusted gross margin expanded 260 bps to 48.1%, and adjusted EBITDA rose 36% to $14.4 million. Nonclinical revenue declined 15% to $14.5 million, with pharma down 26% partially offset by 17% growth in ODS. The company ended with $145.5 million in cash and raised $316 million via convertible notes, retiring $276 million of prior debt.

Company Outlook & Strategy: Management raised full-year 2026 revenue guidance to $802 million-$806 million and adjusted EBITDA guidance to $56 million-$58 million. Clinical growth is now expected in the low teens, with NGS growth in the mid-20s. The company remains focused on durable, profitable growth through higher-value testing, reimbursement wins, and commercial expansion. NeoGenomics reiterated that nonclinical/pharma is not core to the long-term strategy, while clinical oncology diagnostics remains the main growth engine. Management expects mid-single-digit revenue contribution from RaDaR ST and PanTracer Liquid in 2026, with more meaningful impact in later years.

Key Industry Trends: The company highlighted strong demand in community oncology, where physicians want guideline-driven, low-friction workflows and fast turnaround times. Mix shift toward larger NGS panels and higher-value testing continues across the market. Management also emphasized broader adoption of liquid biopsy, MRD, and comprehensive genomic profiling, along with increased integration into EHR workflows such as Epic Aura. Reimbursement remains a major industry lever, especially for MRD adoption and broader commercialization.

Operational Highlights: NeoGenomics reorganized its commercial team into two dedicated ecosystems: oncology and pathology, with roughly 60+ people in each. The Lab of the Future initiative drove margin gains through automation, digital pathology, instrument upgrades, NeoLIMS, procurement, and footprint optimization. The company closed two dry labs, exited low-margin non-oncology business from Pathline, and completed the first clinical assay transition to NovaSeq X for liquid biopsy. Product momentum remained strong for PanTracer Family, PanTracer LBx, RaDaR ST, and PTEN companion diagnostic launches. New RaDaR ST indication submissions now total three, with two Medicare-reimbursed indications already active.

Challenges & Risks: The main challenge remains the underperformance of the nonclinical pharma business, which management said is below expectations due to weaker revenue pull-through despite stronger bookings. Pharma revenues were cut for the full year, though management believes the business may be near a bottom. Other risks include reimbursement timing for RaDaR ST, ongoing reliance on payer coverage expansion, potential competitive dynamics in liquid biopsy and MRD, and the impact of high-volume, low-value contract expiration on quarterly volume comparisons. The DOJ settlement also caused a roughly $10 million cash outflow, though it had already been reserved.

Key Analyst Questions & Responses: Analysts focused on NGS sustainability, pharma strategy, AUP durability, RaDaR ST reimbursement timing, OpEx leverage, and private payer coverage. Management said NGS growth is durable and raised guidance to mid-20s, driven by mix shift to larger panels. Pharma was characterized as non-core and mainly useful for early access, R&D learning, and future clinical product development. AUP strength was attributed to RCM improvements and high-value mix shift, with some durability expected into 2027. For RaDaR ST, management expects additional reimbursement decisions by year-end and in 1H27, with meaningful acceleration in late 2027 into 2028. On costs, management expects G&A leverage to improve into the low 30s as a percent of revenue in 2026 and potentially below 30% in 2027.